Related Experiment Videos
Steroids in the hemolytic uremic syndrome
N Perez1, F Spizzirri, R Rahman
1Immunology Unit, Hospital de Niños Sor. Maria Ludovica, La Plata, Argentina.
Pediatric Nephrology (Berlin, Germany)
|April 16, 1998
Summary
Steroids did not significantly alter most outcomes in children with hemolytic uremic syndrome (HUS). However, methylprednisone was associated with a faster decline in serum creatinine levels during the acute phase of HUS.
Area of Science:
- Pediatric Nephrology
- Clinical Pharmacology
Background:
- Hemolytic uremic syndrome (HUS) is a serious condition affecting children.
- The efficacy of steroid treatment in HUS remains a subject of investigation.
Purpose of the Study:
- To evaluate the clinical benefit of methylprednisone in children with acute hemolytic uremic syndrome.
- To assess the impact of steroids on neurological, hematological, and nephrological parameters.
Main Methods:
- A randomized, double-blinded, placebo-controlled trial involving 92 children with typical HUS.
- Patients received either methylprednisone (5 mg/kg/day for 7 days) or a placebo.
- Outcomes included neurological, hematological, and nephrological variables.
Main Results:
- No significant differences were observed in convulsive episodes or transfusion needs between groups.
- Serum creatinine levels declined significantly between days 1 and 10 in the steroid group (P = 0.001).
- In patients with anuria, steroid treatment was associated with reduced median serum creatinine on day 10 (P = 0.01).
Conclusions:
- Oral steroids do not appear to modify major hematological, neurological, or nephrological parameters in acute childhood HUS.
- Steroid treatment may be linked to a more rapid improvement in serum creatinine levels.